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Abstract
Purpose The introduction of ligands targeting prostate-specific membrane antigen (PSMA), especially 68Ga-PSMA-11, has
changed the management of patients with prostate cancer (PCa). 18F-Labelled ligands can be produced in larger amounts and
therefore can improve availability for a larger group of patients. The aim of this study was to evaluate the diagnostic performance
of the recently introduced 18F-PSMA-1007 in patients with recurrent PCa.
Methods This retrospective analysis included 100 consecutive patients with biochemical relapse (mean age 68.75 ± 7.6 years)
referred for PSMA PET/CT. Whole-body PET/CT imaging (from the lower limbs to the skull) was performed in all patients
120 min after injection of 338 ± 44.31 MBq 18F-PSMA-1007. Prostatectomy, radiation beam therapy of the prostate bed and
androgen-deprivation therapy had been performed in 92%, 45% and 27% of the patients, respectively. Radiation beam therapy of
the prostate bed had been performed in addition to surgery in 38 patients (38%) and 10 patients (10%) had received all three
therapy modalities. The probability of a 18F-PSMA-1007 PET/CT scan suggestive of pathology was compared with the Gleason
score (GS) and PSA level.
Results Of the 100 patients, 95 (95%) showed at least one pathological finding on 18F-PSMA-1007 PET/CT. The overall median
PSA level was 1.34 ng/ml (range 0,04–41.3 ng/ml). The rates of pathological scans were 86%, 89%, 100% and 100% among
patients with PSA levels ≤0.5, 0.51–1.0, 1.1–2.0 and > 2.0 ng/ml, respectively. The median GS was 7 (range 5–10). The majority
of patients (70) with a GS available had a score in the range 7–9. The rate of pathological scans in these patients was 93% (65/70).
The median SUVmax values of the pathological findings were 10.25, 14.32, 13.16 and 28.87 in patients with PSA levels ≤0.5,
0.51–1.0, 1.1–2.0 and >2.0 ng/ml, respectively. The median SUVmax in patients with a PSA level of >2.0 ng/ml was significantly
higher than in all other PSA groups.
Conclusion 18F-PSMA-1007 PET/CT can detect recurrent PCa in a high percentage of patients with biochemical relapse. The
probability of a pathological 18F-PSMA-1007 PET/CT scan seems to be high even in patients with a low PSA level ≤0.5 ng/ml,
and this may have a significant impact on the management of this relevant group of patients.
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Introduction
Prostate cancer (PCa) is the most frequent tumour disease in
men worldwide [1]. Biochemical relapse is frequent after ini-
tial curative treatment, especially in patients with high-risk
PCa. Conventional imaging with, for example, computed to-
mography (CT) and magnetic resonance imaging (MRI), are
insufficient in detecting tumour lesions due to their low sen-
sitivity and specificity. During recent years targeted imaging
of prostate-specific membrane antigen (PSMA), also known
as glutamate carboxypeptidase II, N-acetyl-α-linked acidic
dipeptidase I or folate hydrolase, has opened a new chapter
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in the diagnostic management of patients with PCa [2–6].
PSMA is a type II transmembrane glycoprotein that is strongly
overexpressed in PCa cells. The level of PSMA expression
rises with increasing tumour dedifferentiation and is higher in
hormone-refractory cancers [7–9].
Because of the larger activity amount of cyclotron-
produced 18F compared with the limited activity of 68Ga de-
rived from 68Ge/68Ga generator elution, and its longer half-life
and higher physical spatial resolution, 18F has advantages over
68Ga [10]. Furthermore, the very low urinary activity in 18F-
PSMA-1007 PET/CT scans seems to be another advantage,
which makes this new imaging pharmaceutical highly inter-
esting for the differentiation of lymph node metastases of re-
current PCa from urinary activity in the ureter or for the dif-
ferentiation of local relapse from the urinary bladder [11].
The first clinical experience in single cases or case series
with 18F-PSMA-1007 has shown the potential of this new
radiopharmaceutical in patients with PCa [11–14]. The aim
of the present study was to evaluate the performance of 18F-
PSMA-1007 in detecting PCa recurrence or metastases in pa-
tients with biochemical relapse.
Materials and methods
Patients
FromOctober 2017 toMay 2018, 212 patients were examined
with 18F-PSMA-1007 PET/CT as part of clinical routine. Of
these patients, 100 were referred for the detection of recurrent
PCa. The patients received primary therapy for PCa a median
of 44.3 months before PSMA imaging (range 2–314 months).
In seven patients, the exact time of the first therapy for PCa
was not available. Some of the patients had undergone CT,
MRI or bone scan before PSMA imaging. However, a system-
atic comparison of these data was not possible since the inter-
vals were highly variable and different procedures had been
performed. All other imaging studies performed before PET/
CT had been negative. Of the 100 patients, 28 had been
analysed previously in a dual time scanning analysis [14].
Patient characteristics are given in Table 1. Patients
with no primary therapy with curative intent or patients
referred for PSMA radioligand therapy were not includ-
ed in the current analysis (Fig. 1). Prostatectomy, radi-
ation beam therapy and androgen-deprivation therapy
had been performed in 92%, 45% and 27% of the pa-
tients. Radiation beam therapy in addition to surgery
had been performed in 38 patients (38%) and 10 pa-
tients (10%) had received all three therapy modalities.
All patients received detailed information about the im-
aging procedures and provided signed informed consent
according institutional guidelines.
Imaging procedures and preparation
of 18F-PSMA-1007
18F-PSMA-1007 was produced in a GE TracerLab MX syn-
thesizer according to the one-step procedure described by
Cardinale et al. and standard operation procedures described
previously [14, 15] including sterile filtration of the final batch
solution. 18F-PSMA-1007 precursor, cassettes and reagents
for the synthesis of 18F-PSMA-1007 as well as the synthesis
sequence for fully automatic production with a GE TracerLab
MX module were obtained from ABX GmbH (Radeberg,
Germany). The final injection solution of the 18F-PSMA-
1007 batch was clear, colourless and particle-free, and had a
mean radiochemical purity of 96.5 ± 1.1% (range 95–99%) as
determined by high-performance liquid chromatography.
Unreacted 18F-fluoride or 18F-fluoride resulting from com-
pound cleavage was not detected by thin-layer chromatogra-
phy. The pH of the batch solution ranged from 5.9 to 7.8 and
the endotoxin content was <5.0 endotoxin units/ml. The con-
centrations of ethanol and dimethyl sulfoxide (DMSO) as re-
sidual solvents were measured by gas chromatography (etha-
nol 29.6–31.6 mg/ml; DMSO 0.25–0.68 mg/ml). The osmo-
lality ranged from 1,110 to 1,300 mOsmol/kg.
Patients received 4 MBq/kg body weight with a maximum
of 400 MBq per patient (mean injected activity 338 ±
44.31 MBq). Scanning was performed 120 min after injection
from the lower limbs to the skull. Patients were asked to empty
their bladder before the scan. Images were acquired with a
scan time of 3 min per bed position on a Siemens mCT scan-
ner (Siemens Healthcare, Knoxville, TN). Images were
Table 1 Characteristics of the 100 included patients
Characteristic Value
Age (years)
Mean ± SD 68.75 ± 7.6
Median (range) 70.44 (47.36–85.82)
Administered activity (MBq)
Mean ± SD 338.02 ± 33.31
Median (range) 334 (200–412)
Gleason scorea
Mean ± SD 7.5 ± 1.01
Median (range) 7 (5–10)
PSA level at PET (ng/ml)
Mean ± SD 3.36 ± 6.11
Median (range) 1.34 (0.04–41.3)
Prior therapies, n (%)
Prostatectomy 92 (92)
Radiation beam therapy to prostate bed 45 (45)
Androgen-deprivation therapy 27 (27)
SD standard deviation, PSA prostate-specific antigen
a In 76 patients; data from 24 patients missing
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reconstructed using the standard software provided by the
manufacturer. For attenuation correction, a low-dose CT scan
was performed in accordance with the PET imaging. Contrast-
enhanced CT of the abdomen and pelvis was only performed
if no recent CT or MRI scans were available.
Image analysis
Coregistered images were analysed using syngovia software,
version: VB20A (Siemens Healthcare). According to institu-
tional procedures all scans were analysed by two board-
certified nuclear medicine physicians and radiologists at an
interdisciplinary conference for reporting. Absence of mor-
phological changes was regularly found and were classified
as bone metastases and local recurrence. The sensitivity of CT
for these types of metastases is known to be limited, and thus
high focal tracer uptake in these areas was considered sugges-
tive of bone metastases or local recurrence despite a lack of
morphological correlation. In lesions characteristic of PCa,
volumes of interest were placed on the plane with highest
uptake, and maximum standardized uptake values (SUVmax)
were measured and documented. Focal tracer uptake above
local background in morphologically visible lesions on CT
was considered as PSMA-positive. Any visible PCa lesions
were analysed unless the patients had more than three lesions,
in which case, a maximum of three lesions were analysed.
This kind of selection avoids overestimation of SUVs as oth-
erwise dominant lesions would be preferentially selected.
Typical pitfalls such as PSMA uptake in sacral and coeliac
ganglia or in the stellate ganglia were frequently observed
but were not considered pathological [16].
Statistical analysis
SPSS Statistics 25 (IBM Inc. Armonk, NY, USA)was used for
statistical analysis. Descriptive statistics are absolute and
relative frequencies, mean or median and standard deviation
or range, were used to characterize the study population. For
subgroup analysis, patients were divided into four groups de-
pending on their prostate-specific antigen (PSA) level: ≤0.5,
0.51–1.0, 1.1–2.0 and >2.0 ng/ml. The Mann-Whitney test
was used to evaluate the significant differences of the median
SUVmax (of the lesion with maximum uptake from each pa-
tient) between PSA groups. A P value <0.05 was considered
significant and noticeable.
Results
The analysis included 100 consecutive patients (mean age
68.75 ± 7.6 years) who were referred for 18F-PSMA-1007
PET/CT for evaluation and localization of biochemical re-
lapse. None of the patients showed any kind of adverse event
or clinically detectable pharmacological effect following in-
jection of 18F-PSMA-1007. In 95 of the 100 patients (95%) at
least one lesion suggestive of PCa was detected on 18F-
PSMA-1007 PET/CT. The patient-based sensitivity was there-
fore 95% (95% confidence interval 91–99%). In total, 213
lesions characteristic of PCa (37 local relapses, 107 lymph
node metastases, 67 bone metastases and 2 soft tissue metas-
tases) were detected in 95 patients, and in 29 patients relapse
was exclusively lymph node metastases, in 16 patients exclu-
sively bone metastases and in 15 patients exclusively local
relapse. Table 2 presents the average SUVmax of all included
lesions. Examples of a bone lesion, a lymph node and a local
relapse are given in Figs. 2, 3 and 4.
Of patients with a PSA level ≤2.0 ng/ml, 92% were PET-
positive. The rates of pathological 18F-PSMA-1007 PET/CT
scans in relation to PSA level and Gleason score (GS) are
presented in Fig. 5. In total, 18F-PSMA-1007 PET/CT was
negative in five patients, three with a PSA level ≤0.5 ng/ml
and two with a PSA level in the range 0.51–1.0 ng/ml.
212 patients referred for
18F-PSMA-1007 PET/CT 
Study population
n = 100 referred for
evaluation and localization of biochemical relapse
n = 112 patients excluded
(already known PSMA metastases,
patients referred to PSMA tergeted
radioligand therapy or patients without
curative intended therapy)
Fig. 1 Flow chart of patient
selection
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The majority of patients (70) with a GS available had a
score in the range 7–9. The detection rate in these patients
was 93% (65/70). The median SUVmax values of the patho-
logical findings in patients with PSA levels ≤0.5, 0.51–1.0,
1.1–2.0 and > 2.0 ng/ml were 10.25 (range 3.98–48.99), 14.32
(range 4.36–38.61), 13.16 (range 3.14–136.18) and 28.87
(range 5.03–248.27), respectively. The median SUVmax in pa-
tients with a PSA level >2.0 ng/ml was significantly higher
than that in patients in the other PSA groups (>2.0 ng/ml vs.
≤0.5 ng/ml, P = 0.001; vs. 0.51–1.0 ng/ml, P = 0.005; vs. 1.1–
2.0 ng/ml, P = 0.027). There were no significant differences
among the other PSA groups.
Discussion
PSMA-targeted imaging has achieved a leading role in the
management of PCa patients during recent years overcoming
the challenging lack of sensitivity and specificity of conven-
tional imaging modalities. In the present study the perfor-
mance of 18F-PSMA-1007 in detecting PCa lesions in patients
with biochemical relapse was evaluated.18F-PSMA-1007
PET/CT scans in 100 consecutive patients referred for evalu-
ation and localization of biochemical relapse were retrospec-
tively analysed. Of all the patients included in this analysis,
95% showed at least one lesion with characteristics suggestive
Table 2 Average SUVmax of PCa
lesions of all types Lesion type No. of lesions SUVmax
Mean ± SD Minimum Maximum Median
All lesions 213 21.52 ± 29.8 2.49 248.28 11.45
Local relapse 37 18.29 ± 23.78 3.87 137.94 10.64
Lymph node metastases 107 26.03 ± 34.51 2.59 248.28 16.1
Bone metastases 67 16.57 ± 23.59 2.49 136.18 7.5
Soft tissue metastases 2 6.82 ± 3.7 4.19 9.46 6.8
SD standard deviation, PCa prostate cancer
Fig. 2 18F-PSMA-1007 PET/CT
imaging (left axial images, right
sagittal images) in a 72-year-old
patient with biochemical relapse
(PSA level 0.86 ng/ml) and with a
Gleason score of 7b (4 + 3). The
images show focal right-sided
tracer uptake in the prostate bed
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of PCa on 18F-PSMA-1007 PET/CT. A recent case series of
12 patients revealed a detection rate of 75% [17], which is
lower than in the present study, but the detection rate found
in that study might have been due to the small number of
patients. In the study mentioned, 62% of the patients who
had a PSA level ≤2.0 ng/ml had a pathological scan, whereas
in our study 92% of the patients (56/61) with a PSA level of
≤2.0 ng/ml had a pathologic scan.
The PET-positive rate in the present study was higher than
the detection rate in a study investigating the performance of
68Ga-PSMA-11 PET/CT in 1007 patients with biochemical
relapse (the largest group investigated so far) [3]. In that study
the detection rate was 79.5% in patients with a median PSA
level of 2.2 ng/ml compared with 95% in the present study
and a median PSA level of 1.34 ng/ml. In another study also
using 68Ga-PSMA-11, the detection rate was 89.5% in 248
patients with biochemical relapse and a median PSA level of
1.99 ng/ml [18]. In that study, the detection rate in patients
with a PSA level <0.5 ng/ml was 57.9% (11/19) compared
with a rate of 86% (18/21) in our study. Although the patient
groups are not directly comparable (e.g. different proportions
of patients with previous surgical treatment), our results could
indicate that 18F-PSMA-1007 has a higher sensitivity than
68Ga-PSMA-11. However, further studies including more pa-
tients are mandatory to further analyse the sensitivity of 18F-
PSMA-1007.
In the present study, local relapse was detected in 37% of
patients (37/100), which is considerably higher than found
in a recent study using 68Ga-PSMA-11 in which local re-
lapse was detected in 4% of patients (13/319) [2]. Our re-
sults suggest that 18F-PSMA-1007 might be superior to
68Ga-PSMA-11, especially in patients with a low PSA level.
However, this suggestion must be further evaluated in a
head to head comparison, which is not yet available.
Furthermore, it is well known from 68Ga-PSMA-11 and
18F-PSMA-1007 studies that PCa lesions are shown with
better contrast and higher tracer uptake after longer uptake
times (e.g. 3 h rather than 1 h after injection) [2, 6, 14]. This
indicates that imaging with 18F-PSMA-1007 is probably
more advantageous at 2 h than at 1 h after injection, which
has become common with 68Ga-PSMA-11 at most centres.
The longer half-life and higher injected activities allow
high-quality delayed images, higher lesion uptake and su-
perior clearance of background activity. The higher detec-
tion rate may therefore be because of the superior differen-
tiation of ureter and bladder activity from local recurrence
and locoregional lymph node metastasis [11, 14]. The con-
fidence in diagnosing local recurrence is thus enhanced.
Particularly in patients with a low PSA level, radiotherapy
of local recurrences may induce secondary complete remis-
sion. A reliable imaging procedure for use in patients with
increasing but still low PSA levels is thus of the utmost
Fig. 3 18F-PSMA-1007 PET/CT imaging (axial images: left PET, centre
CT, right fused PET/CT) in a 73-year-old patient with biochemical
relapse (PSA level 1.05 ng/ml) after radical prostatectomy and prior
antiandrogen therapy and radiation to prostate bed (Gleason score not
available). The images show bone metastases in the left pelvis and in
the adjacent os sacrum. An additional presacral lesion is seen on the left
side suggestive of lymph node metastasis
Fig. 4 18F-PSMA-1007 PET/CT imaging (axial images: left PET, centre
CT, right fused PET/CT) in a 59-year-old patient with biochemical
relapse (PSA level 0.54 ng/ml) after radical prostatectomy and with a
Gleason score of 7b (4 + 3). Images show a 5-mm lymph node lesion
(arrow) with high tracer uptake along the left iliac artery
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clinical relevance. The nonsignificant differences in median
SUVmax among the subgroups of patients with a PSA level
≤2.0 ng/ml underlines the high detection rates revealed in
the present analysis in patients with a very low PSA level
(e.g. ≤0.5 ng/ml). A lower PSA threshold level can thus not
be recommended since tumour lesions can be visualized
with high sensitivity due to high uptake.
High liver and bowel uptake of 18F-PSMA-1007 has been
reported. This was also found in the present group of patients.
Since isolated liver metastases occur infrequently and bowel
metastases very rarely, we consider that the high uptake in these
organs would not cause a marked deterioration in the sensitivity
of the tracer. In the present study, the sensitivity of 18F-PSMA-
1007 PET/CT seemed to be independent of the GS. Prior stud-
ies using 68Ga-PSMA-11 have only shown a probable tendency
for higher detection rates with increasing GS [3].
The lack of histopathology was a limitation of the present
study. Therefore, we cannot exclude false-positive lesions,
although the images were analysed by physicians with long
experience of PET imaging, especially PCa imaging with
PSMA-targeted radioligands.
Conclusion
18F-PSMA-1007 PET/CT can detect recurrent PCa in a high
percentage of patients with biochemical relapse. The proba-
bility of a pathological 18F-PSMA-1007 PET/CT seems to be
high even in patients with a low PSA level of ≤0.5 ng/ml,
which may have a significant impact in the further clinical
management of patients. Prospective controlled trials are man-
datory to validate these data.
Acknowledgments We thank the Radiochemistry Group at the
Department of Nuclear Medicine for their highly reliable production of
18F-PSMA-1007, and the technologists for their support.
Funding The publication of this article was supported by funds from the
European Association of Nuclear Medicine (EANM).
N
u
m
b
er
 o
f 
P
at
ie
n
ts
PSA Value
N
u
m
b
er
 o
f 
P
at
ie
n
ts
Gleason Score
a
b
18
(86%)
16
(89%)
22
(100%)
39
(100%)
3
2
0
5
10
15
20
25
30
35
40
45
0
GSC 5 GSC 6 GSC 7 GSC 8 GSC 9 GSC 10
5
10
15
20
25
30
35
40
45
50
≤0.5 0.51 - ≤1.0 1.1 - ≤ 2.0 >2.0
PET-positive patients
PET-negative patients
Fig. 5 Probability of pathological
18F-PSMA-1007 PET/CT in
relation to PSA level (a) in 100
patients and in relation to Gleason
score (b) in 76 patients. Blue
columns show the number and
percentage of patients with a
pathological 18F-PSMA-1007
PET/CT scan. Grey columns
show the number and percentage
of patients with a negative PET
scan
2060 Eur J Nucl Med Mol Imaging (2018) 45:2055–2061
Compliance with ethical standards
Conflicts of interest The University ofMünster received consulting fees
from ABX GmbH, Radeberg, Germany, for K.R. and M.B. Additionally
K.R. is a scientific consultant/advisor to ABX GmbH. The authors de-
clare they have no conflict of interest according to the subject and matter
of the present article.
Ethical approval All procedures performed in studies involving human
participants were in accordance with the ethical standards of the institu-
tional and/or national research committee and with the principles of the
1964 Declaration of Helsinki and its later amendments or comparable
ethical standards. This article does not describe any studies with animals
performed by any of the authors. According to data protection guidelines,
formal ethical approval for retrospective studies is not necessary.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer
J Clin. 2015;65(1):5–29. https://doi.org/10.3322/caac.21254.
2. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart
HG, Eder M, et al. The diagnostic value of PET/CT imaging with
the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of
recurrent prostate cancer. Eur J Nucl Med Mol Imaging.
2015;42(2):197–209. https://doi.org/10.1007/s00259-014-2949-6.
3. Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier
W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11
(HBED-CC) PET/CT in patients with recurrent prostate cancer:
evaluation in 1007 patients. Eur J Nucl Med Mol Imaging.
2017;44(8):1258–68. https://doi.org/10.1007/s00259-017-3711-7.
4. Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ,
Schrader AJ, et al. Correlation of Intraprostatic tumor extent with
68Ga-PSMA distribution in patients with prostate cancer. J Nucl
Med. 2016;57(4):563–7. https://doi.org/10.2967/jnumed.115.
169243.
5. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut
M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-
labelled PSMA ligand and (18)F-choline-based PET/CT for the
diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol
Imaging. 2014;41(1):11–20. https://doi.org/10.1007/s00259-013-
2525-5.
6. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG,
Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled
PSMA ligand for the diagnosis of prostate cancer: biodistribution in
humans and first evaluation of tumour lesions. Eur J Nucl MedMol
Imaging. 2013;40(4):486–95. https://doi.org/10.1007/s00259-012-
2298-2.
7. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression
of the prostate-specific membrane antigen. Cancer Res. 1994;54(7):
1807–11.
8. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific
membrane antigen expression is greatest in prostate adenocarcino-
ma and lymph node metastases. Urology. 1998;52(4):637–40.
9. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K,
Petrylak D, et al. Upregulation of prostate-specific membrane anti-
gen after androgen-deprivation therapy. Urology. 1996;48(2):326–
34.
10. Kesch C, Kratochwil C, Mier W, Kopka K, Giesel FL. 68Ga or 18F
for prostate cancer imaging? J Nucl Med. 2017;58(5):687–8.
https://doi.org/10.2967/jnumed.117.190157.
11. Rahbar K, Weckesser M, Ahmadzadehfar H, Schafers M, Stegger
L, Bogemann M. Advantage of 18F-PSMA-1007 over 68Ga-
PSMA-11 PET imaging for differentiation of local recurrence vs.
urinary tracer excretion. Eur J Nucl Med Mol Imaging. 2018;45(6):
1076–7. https://doi.org/10.1007/s00259-018-3952-0.
12. Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M,
Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radi-
ation dosimetry and histopathological validation of tumor lesions in
prostate cancer patients. Eur J Nucl MedMol Imaging. 2017;44(4):
678–88. https://doi.org/10.1007/s00259-016-3573-4.
13. Giesel FL, Kesch C, YunM, Cardinale J, HaberkornU, KopkaK, et
al. 18F-PSMA-1007 PET/CT detects micrometastases in a patient
with biochemically recurrent prostate cancer. Clin Genitourin
Cancer. 2017;15(3):e497–9. https://doi.org/10.1016/j.clgc.2016.
12.029.
14. Rahbar K, Afshar-Oromieh A, Bogemann M, Wagner S, Schafers
M, Stegger L, et al. (18)F-PSMA-1007 PET/CT at 60 and 120
minutes in patients with prostate cancer: biodistribution, tumour
detection and activity kinetics. Eur J Nucl Med Mol Imaging.
2018;45(8):1329–34. https://doi.org/10.1007/s00259-018-3989-0.
15. Cardinale J, Schafer M, Benesova M, Bauder-Wust U, Leotta K,
Eder M, et al. Preclinical evaluation of 18F-PSMA-1007, a new
prostate-specific membrane antigen ligand for prostate cancer im-
aging. J Nucl Med. 2017;58(3):425–31. https://doi.org/10.2967/
jnumed.116.181768.
16. Backhaus P, Noto B, Avramovic N, Grubert LS, Huss S, Bogemann
M, et al. Targeting PSMA by radioligands in non-prostate disease-
current status and future perspectives. Eur J Nucl Med Mol
Imaging. 2018;45(5):860–77. https://doi.org/10.1007/s00259-017-
3922-y.
17. Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, et al.
Biochemical recurrence of prostate cancer: initial results with
[(18)F]PSMA-1007 PET/CT. J Nucl Med. 2018;59(4):632–5.
https://doi.org/10.2967/jnumed.117.196329.
18. Eiber M,Maurer T, SouvatzoglouM, Beer AJ, Ruffani A, Haller B,
et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248
patients with biochemical recurrence after radical prostatectomy. J
Nucl Med. 2015;56(5):668–74. https://doi.org/10.2967/jnumed.
115.154153.
Eur J Nucl Med Mol Imaging (2018) 45:2055–2061 2061
